ABSTRACT
Objective To study the clinical and pathological features of hepatic steatosis in patients with chronic hepatitis B (CHB)based on a matched case-control study.Methods Cross-sectional study was carried out on CHB patients who received liver biopsy in the Department of Infectious Diseases, Shunde First People′s Hospital from January 2006 to December 2014.Clinical data of the patients were collected.A total of 216 matched pairs were created according to gender and age.The clinical and pathological feathers of both groups were compared and analyzed. Quantitative data with normal distribution were compared by t test and those with abnormal distribution were compared by nonparametric rank sum test of two- or multi-independent samples. Categorical data were compared by χ2 test. Results In matched pairs,rates of overweight/obesity were 84.2% in fatty liver group and 18.5 % in non-fatty liver group (χ2 =189.30,P =0.001 ),patients with high cholesterol in the two groups were 30.6% and 13.4%,respectively (χ2 =18.47,P =0.001 ),high triglycerides were 27.3% and 9.7%, respectively (χ2 =22.15 ,P =0.001),high low-density lipoprotein were 16.7% and 5 .6%,respectively (χ2 =13.50,P =0.001),high uric acid were 31 .0% and 15 .3%,respectively (χ2 =15 .04,P =0.001 ) and rates of alcohol history were 38.9% and 25 .9%,respectively (χ2 =8.08,P =0.001).The differences of hepatitis B virus (HBV)DNA and status of hepatitis B e antigen between the two groups were not statistically significant (both P >0.05 ).Compared to fatty liver group,rates of hepatic inflammation activity degree ≥ 3 (54.6% vs 37.5 %,χ2 = 12.75 ,P <0.01 )and fibrosis staging ≥ 3 (53.2% vs 41 .7%,χ2 =5 .80,P =0.016)in non-fatty liver group were both significantly higher.Conclusions CHB patients with overweight/obesity,high cholesterol,high triglycerides,high low-density lipoprotein,high uric acid and drinking history are more likely to develop hepatic steatosis.The inflammatory grade and fibrosis stage in non-fatty liver group are more serious than those in fatty liver group.
ABSTRACT
ObjectiveTo analyze the prevalence and clinical features of hepatic steatosis in patients with chronic hepatitis B. MethodsThe clinical data of patients with chronic hepatitis B who were hospitalized at the Department of Infectious Diseases, the First People′s Hospital of Shunde, Guangdong, China, from January 2006 to December 2014, were retrospectively collected for analysis and comparison of clinical and pathological indicators. The patients were divided into fatty liver group and non-fatty liver group depending on the presence or absence of fatty liver. Continuous data of the two groups were compared using the t test and categorical data were compared using the χ2 test. If data were not normally distributed, comparisons were made using the Mann-Whitney U test. ResultsThe incidence of fatty liver increased with age (P＜0.05) and peaked at an age of ≥45 years in both groups. Fatty liver was more likely to occur in men than in women below 30 years and between 30 and 44 years (P＜0.05). Diabetes, abnormal levels of cholesterol, triglycerides, low-density lipoprotein, and uric acid, and a history of alcohol consumption were significantly more frequent in the fatty liver group than in the non-fatty liver group (P＜0.05). Levels of body mass index, gamma-glutamyl transpeptidase, albumin, blood urea nitrogen, creatinine, uric acid, glucose, total cholesterol, triglycerides, low-density lipoprotein, apolipoprotein A, apolipoprotein B, aspartate aminotransferase were significantly different between the two groups (P＜0.05). Inflammation and fibrosis were significantly milder in the fatty liver group compared with the non-fatty liver group (P＜0.05). Patients in the non-fatty liver group were more likely to be complicated by grade 3 liver inflammation and stage 3 fibrosis (P=0.001 and P=0.015). ConclusionFatty liver patients are more likely to present with glucose and lipid metabolism disorder. Hepatic steatosis is not significantly correlated with HBeAg, but may be somewhat associated with HBV DNA, inflammation grade and fibrosis stage. Further studies are needed to establish their connections. .
ABSTRACT
<p><b>OBJECTIVE</b>To explore the change of serum gamma-glutamyltransferase (GGT) and its diagnosis value in chronic hepatitis B (CHB) patients with different degrees of liver damage.</p><p><b>METHODS</b>Alanine-aminotransferase (ALT), aspartate-aminotransferase (AST) and GGT were measured in 221 CHB patients. Liver biopsy was conducted simultaneously to determine the inflammation grade and fibrosis stage of the liver tissues.</p><p><b>RESULTS</b>The rate of normal GGT in pathologically diagnosed mild and severe CHB patients was 90.4% and 12.3%, respectively (P<0.01). Increased level of GGT was parallel to the degree of liver pathological change (P<0.01). In active CHB patients, GGT rose with the ALT increase with a positive linear correlation between them (r=0.464, P<0.001). In pathologically diagnosed mild CHB patients, GGT had a tendency of rapidly declining to normal levels with ALT. In moderate CHB patients, GGT fluctuated at a relatively high level, and in severe CHB patients GGT exhibited a deviation from GGT.</p><p><b>CONCLUSIONS</b>GGT is conducive to improve the coincident rate between the clinical and pathological diagnosis of CHB.</p>
Subject(s)
Adult , Female , Humans , Male , Alanine Transaminase , Blood , Aspartate Aminotransferases , Blood , Fibrosis , Hepatitis B, Chronic , Diagnosis , Pathology , Predictive Value of Tests , Severity of Illness Index , Time Factors , gamma-Glutamyltransferase , BloodABSTRACT
Objective To evaluate the value of Microparticle Enzyme Immunoassay(MEIA),a quantitative assay, in the diagnosis and treatment of chronic hepatitis B (CHB). Methods MEIA, Enzyme linked immunoabsorbent assay (ELISA), and quantitative PCR were used to detect e antigen, hepatitis B serum markers, and the quantity of HBV DNA in 249 CHB patients and 32 non CHB patients respectively. Expression of HBcAg in Liver tissue was detected by using S P method. These measures were used to illuminate the relationships among serum e antigen quantity, hepatitis B serum markers, the quantity of HBV DNA, the quantity of HBcAg in hepatocytes, and pathologic diagnosis of liver tissues. Results 1. The sensitivity of MEIA (80.28%) to detect serum e antigen is higher than that of ELISA (69.01%)( ? 2=9.312, P =0.002).2. The serum e antigen quantity is positively correlated with the logarithm of the quantity of HBV DNA ( r =0.411, P =0.000). 3. The level of serum e antigen is positively correlated with the semi quantitative of HBcAg in hepatocytes ( r =0.646, P =0.000). 4. The serum e antigen quantity is negatively correlated with pathologic degree of liver tissues ( r =-0.172, P =0.006). Conclusions MEIA is a sensitive, stable, and reliable method to assay the serum e antigen quantity which could be used to evaluate the replication of HBV and the degree of liver damage.